Free Trial
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis

$58.90
+5.56 (+10.42%)
(As of 07/12/2024 ET)
Today's Range
$53.32
$60.64
50-Day Range
$38.82
$58.90
52-Week Range
$3.03
$60.64
Volume
613,054 shs
Average Volume
332,215 shs
Market Capitalization
$629.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.25

Corbus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
24.4% Upside
$73.25 Price Target
Short Interest
Bearish
7.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.56mentions of Corbus Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.53 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.11) to ($5.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

304th out of 917 stocks

Pharmaceutical Preparations Industry

134th out of 435 stocks

CRBP stock logo

About Corbus Pharmaceuticals Stock (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Stock Price History

CRBP Stock News Headlines

Corbus Pharmaceuticals (NASDAQ:CRBP) Rating Reiterated by Oppenheimer
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Gap Up to $50.97
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
CRBP Corbus Pharmaceuticals Holdings, Inc.
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2024
Today
7/13/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRBP
Employees
19
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$73.25
High Stock Price Target
$85.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+24.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-44,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
($1.56) per share

Miscellaneous

Free Float
10,260,000
Market Cap
$629.64 million
Optionable
Optionable
Beta
2.59

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Yuval Cohen Ph.D. (Age 49)
    CEO & Director
    Comp: $907.78k
  • Mr. Sean F. Moran CPA (Age 66)
    M.B.A., Chief Financial Officer
    Comp: $609.28k
  • Ms. Lindsey Smith
    Head of Corporate Communications & Patient Advocacy
  • Ms. Christina Bertsch
    Head of Human Resources
  • Dr. Dominic Smethurst M.A. (Age 49)
    M.D., Chief Medical Officer

CRBP Stock Analysis - Frequently Asked Questions

How have CRBP shares performed this year?

Corbus Pharmaceuticals' stock was trading at $6.04 at the beginning of the year. Since then, CRBP stock has increased by 875.2% and is now trading at $58.90.
View the best growth stocks for 2024 here
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.26.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Matinas BioPharma (MTNB).

This page (NASDAQ:CRBP) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners